Acting as an expert observer on the board

Challenge A private equity (PE) investor was looking for a partner to be retained as an observer on the board of a regenerative medicine/advanced wound-healing company.
Learn More

Providing business development and deal support in antibiotics

Challenge A pharma company that specializes in discovering and developing antibiotics asked us to help expand the search for a development partner in some of its drug candidates.
Learn More

Valuing a cancer immunotherapy asset

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.
Learn More

Valuing multinational pharma company partnerships

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...
Learn More

Supporting a biotech company’s pharma partnerships

Challenge A biotech company needed support with an active partnering process with several major pharma companies.
Learn More

Evaluating a pipeline agreement with a platform technology company

Challenge A division of a multinational pharma company needed support evaluating a pipeline agreement with a platform technology company. The client wanted to know what the overall value of this...
Learn More

Conducting due diligence on a novel interventional cardiology device

Challenge A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with preclinical testing on pigs,...
Learn More

Due diligence on a new biosensor technology

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...
Learn More

Providing an oncology cell therapy reality check

Challenge A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.
Learn More

Due diligence of a small molecule arising from a phenotypic screen

Challenge Our client asked us to conduct a risk assessment and due diligence of a small molecule oncology compound that had been identified from a phenotypic screen. The molecule was in a Phase I/II...
Learn More

Due diligence and valuation of a preclinical kinase inhibitor

Challenge We were commissioned to conduct a comprehensive technical risk assessment and due diligence of a novel preclinical, small molecule, kinase inhibitor.
Learn More

Benchmarking products for the diagnostics market

Challenge A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...
Learn More